SCHEMBL13667385

SCHEMBL13667385

COc1ccc(C(=O)N(C(=O)c2ccc(OC)cc2)c2nccc3[nH]cnc23)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
PARP10 Q53GL7 2/20 0.39
PARP1 P09874 1/20 0.39
PARP2 Q9UGN5 1/20 0.39
PARP4 Q9UKK3 1/20 0.39
MAPT P10636 1/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
BRD4 O60885 1/20 0.38
POLB P06746 1/20 0.38
MMP12 P39900 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
TRPM8 Q7Z2W7 1/20 0.37
DRD2 P14416 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13667389 0.83 EGLN1 (0.43) NPC1RAB9AKMT2APARP1KDM4E
SCHEMBL13667383 0.75 BRD4 (0.57) NPC1RAB9AKMT2AMAPTBRD4
SCHEMBL31146869 0.74 QPCT (0.48) KMT2AMAPTMMP12CYP3A4
SCHEMBL13667386 0.73 EGLN1 (0.39) PARP1POLBMMP12EGLN1
SCHEMBL4694718 0.70 EGLN1 (0.46) RAB9AKMT2APARP1KDM4EHPGD
SCHEMBL4910686 0.65 EGLN1 (0.57) NPC1RAB9AKMT2APARP1KDM4E
SCHEMBL986616 0.65 DRD1 (0.47) KMT2APARP1BRD4POLBMMP12
SCHEMBL29424879 0.65 DRD1 (0.47) KMT2APARP1BRD4POLBMMP12
SCHEMBL2059315 0.64 MAPT (0.54) NPC1KMT2AMAPTKDM4EPOLB
SCHEMBL30527863 0.64 CES2 (0.64) RAB9AKMT2ACA1CA2PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270431-A1 Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270431-A1 Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections REV1, NSUN2, ORC3 NPC1 216/4885RAB9A 2279/4885KMT2A 4643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.